methylcobalamin

ApprovedSmall molecule

Eisai

methylcobalamin is one of 136 small molecule programs targeting Neurotoxicity. It is currently in Approved.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurotoxicityActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Oxidative StressActive, not recruiting

AutismActive, not recruiting

NeurotoxicityApproved

Active, not recruiting

Peripheral NeuropathyPhase 2

Active, not recruiting

Oxidative StressPreclinical

Active, not recruiting

AutismPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Peripheral Neuropathy

#DrugCompanyPhaseTrials

Journavx

Vertex Pharmaceuticals

Phase 3

4 2

Namenda

AbbVie

Phase 3

1 3

Farxiga

AstraZeneca

Phase 3

1 4

Nucynta

CCollegium Pharmaceutical, Inc.

Phase 3

2 5

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 3

1 6

Lamictal

GGlaxo Dba Glaxosmithkline

Phase 3

1 7

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 8

Oxycontin

PProtega

Phase 3

1 9

Calcium Gluconate

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 10

Ixempra

RR-Pharm

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Neurotoxicity

NCT07344974

Clinical

Trials by Indication[1]

Peripheral Neuropathy1 trial

A Randomized Controlled Trial of Mecobalamin Injection and Tablet Treatment Efficacy on Mild to Moderate Diabetic Peripheral Neuropathy

Unknown status·PPeking University Third Hospital·Phase 2·NCT04372316·30 enrolled

Clinical Trial1 trial

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

Completed· Eisai logo

Eisai·Phase 3·NCT03548311·130 enrolled

Neurotoxicity1 trial

Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 4·NCT07344974·78 enrolled

Oxidative Stress1 trial

Treating Oxidative Stress in Children With Autism

Completed·—·N/A·NCT00692315·40 enrolled

Cardiac Surgical Patients1 trial

Preoperative Vitamin B12 and Folic Acid on POCD in Elderly Non-cardiac Surgical Patients

Terminated·XXijing Hospital·N/A·NCT03485404·40 enrolled

1 more indication

Autism1 trial

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

Completed·UUniversity of California, San Francisco·Phase 2/3·NCT00273650·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for methylcobalamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — methylcobalamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for methylcobalamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

methylcobalamin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Peripheral Neuropathy1 trial

Clinical Trial1 trial

Neurotoxicity1 trial

Oxidative Stress1 trial

Cardiac Surgical Patients1 trial

Autism1 trial

References

Drug Info

Quick Facts

Related News